4-Borono-2-F-fluoro-L-phenylalanine PET for Boron Neutron Capture Therapy-oriented Diagnosis: Overview of a Quarter Century of Research

Overview

Journal Ann Nucl Med

Date 2019 Mar 2

PMID 30820862

Citations 22

Authors

Kiichi Ishiwata

Affiliations

Soon will be listed here.

Abstract

4-B-Borono-2-F-fluoro-L-phenylalanine (F-FBPA) was developed for monitoring the pharmacokinetics of 4-B-borono-L-phenylalanine (B-BPA) used in boron neutron capture therapy (BNCT) with positron emission tomography (PET). The tumor-imaging potential of F-FBPA was demonstrated in various animal models. Accumulation of F-FBPA was higher in melanomas than in non-melanoma tumors in animal models and cell cultures. F-FBPA was incorporated into tumors mediated mainly by L-type amino acid transporters in in vitro and in vivo models. Tumoral distribution of F-FBPA was primarily related to the activity of DNA synthesis. F-FBPA is metabolically stable but is incorporated into melanogenesis non-enzymatically. These in vitro and in vivo characteristics of F-FBPA corresponded well to those of B-BPA. Nuclear magnetic resonance and other studies using non-radioactive F-B-FBPA also contributed to characterization. The validity and reliability of F-FBPA as an in vivo probe of B-BPA were confirmed by comparison of the pharmacokinetics of F-FBPA and B-BPA and direct measurement of both F and B in tumors with various doses of both probes administered by different routes and methods. Clinically, based on the kinetic parameters of dynamic F-FBPA PET, the estimated B-concentrations in tumors with continuous B-BPA infusion were similar to those measured directly in surgical specimens. The significance of F-FBPA PET was verified for the estimation of B-concentration and planning of BNCT. Later F-FBPA PET has been involved in B-BPA BNCT of patients with intractable tumors such as malignant brain tumors, head and neck tumors, and melanoma. Usually a static PET scan is used for screening patients for BNCT, prediction of the distribution and accumulation of B-BPA, and evaluation of treatment after BNCT. In some clinical trials, a tumor-to-normal tissue ratio of F-FBPA > 2.5 was an inclusion criterion for BNCT. Apart from BNCT, F-FBPA was demonstrated to be a useful PET probe for tumor diagnosis in nuclear medicine: better tumor-to-normal brain contrast compared with C-methionine, differentiation of recurrent and radiation necrosis after radiotherapy, and melanoma-preferential uptake. Further progress in F-FBPA studies is expected for more elaborate evaluation of B-concentrations in tumors and normal tissues for successful B-BPA BNCT and for radiosynthesis of F-FBPA to enable higher F-activity amounts and higher molar activities.

Citing Articles

LAT1-specific PET radiotracers: Development and clinical experiences of a new class of cancer-specific radiopharmaceuticals.

Achmad A, Hanaoka H, Holik H, Endo K, Tsushima Y, Kartamihardja A Theranostics. 2025; 15(5):1864-1878.

PMID: 39897549 PMC: 11780518. DOI: 10.7150/thno.99490.

Prognostic assessment of F-boronophenylalanine positron emission tomography (BPA-PET) in salvage boron neutron capture therapy for malignant brain tumors.

Lin K, Chen Y, Wang L, Wang Y, Hu L, Ting C Quant Imaging Med Surg. 2024; 14(6):4177-4188.

PMID: 38846276 PMC: 11151257. DOI: 10.21037/qims-23-1769.

PK Modeling of L-4-Boronophenylalanine and Development of Bayesian Predictive Platform for L-4-Boronophenylalanine PKs for Boron Neutron Capture Therapy.

Kim W, Won J, Yi J, Choi S, Lee S, Mun K Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543087 PMC: 10975701. DOI: 10.3390/ph17030301.

A compact scintillator-based detector with collimator and shielding for dose monitoring in boron neutron capture therapy.

Caracciolo A, Ferri T, Borghi G, Carminati M, Protti N, Altieri S Phys Imaging Radiat Oncol. 2024; 29:100556.

PMID: 38405430 PMC: 10891326. DOI: 10.1016/j.phro.2024.100556.

Investigation of the Impact of L-Phenylalanine and L-Tyrosine Pre-Treatment on the Uptake of 4-Borono-L-Phenylalanine in Cancerous and Normal Cells Using an Analytical Approach Based on SC-ICP-MS.

Balcer E, Giebultowicz J, Sochacka M, Ruszczynska A, Muszynska M, Bulska E Molecules. 2023; 28(18).

PMID: 37764328 PMC: 10534874. DOI: 10.3390/molecules28186552.

References

Wittig A, Sauerwein W, Coderre J . Mechanisms of transport of p-borono-phenylalanine through the cell membrane in vitro. Radiat Res. 2000; 153(2):173-80. DOI: 10.1667/0033-7587(2000)153[0173:motopb]2.0.co;2. View

Bendel P, Koudinova N, Salomon Y . In vivo imaging of the neutron capture therapy agent BSH in mice using (10)B MRI. Magn Reson Med. 2001; 46(1):13-7. DOI: 10.1002/mrm.1154. View

Soloway A, Tjarks W, Barnum B, Barth R, Codogni I, Wilson J . The Chemistry of Neutron Capture Therapy. Chem Rev. 2002; 98(4):1515-1562. DOI: 10.1021/cr941195u. View

Barth R, Yang W, Bartus R, Rotaru J, Ferketich A, Moeschberger M . Neutron capture therapy of intracerebral melanoma: enhanced survival and cure after blood-brain barrier opening to improve delivery of boronophenylalanine. Int J Radiat Oncol Biol Phys. 2002; 52(3):858-68. DOI: 10.1016/s0360-3016(01)02734-1. View

Chandra S, Kabalka G, Lorey 2nd D, Smith D, Coderre J . Imaging of fluorine and boron from fluorinated boronophenylalanine in the same cell at organelle resolution by correlative ion microscopy and confocal laser scanning microscopy. Clin Cancer Res. 2002; 8(8):2675-83. View

Nichols T, Kabalka G, Miller L, Khan M, Smith G . Improved treatment planning for boron neutron capture therapy for glioblastoma multiforme using fluorine-18 labeled boronophenylalanine and positron emission tomography. Med Phys. 2002; 29(10):2351-8. DOI: 10.1118/1.1507780. View

Tsuyuguchi N, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Takami T . Methionine positron emission tomography of recurrent metastatic brain tumor and radiation necrosis after stereotactic radiosurgery: is a differential diagnosis possible?. J Neurosurg. 2003; 98(5):1056-64. DOI: 10.3171/jns.2003.98.5.1056. View

Blue T, Yanch J . Accelerator-based epithermal neutron sources for boron neutron capture therapy of brain tumors. J Neurooncol. 2003; 62(1-2):19-31. DOI: 10.1007/BF02699931. View

Kabalka G, Nichols T, Smith G, Miller L, Khan M, Busse P . The use of positron emission tomography to develop boron neutron capture therapy treatment plans for metastatic malignant melanoma. J Neurooncol. 2003; 62(1-2):187-95. DOI: 10.1007/BF02699944. View

10.

Ishiwata K, Shiono M, Kubota K, Yoshino K, Hatazawa J, Ido T . A unique in vivo assessment of 4-[10B]borono-L-phenylalanine in tumour tissues for boron neutron capture therapy of malignant melanomas using positron emission tomography and 4-borono-2-[18F]fluoro-L-phenylalanine. Melanoma Res. 1992; 2(3):171-9. DOI: 10.1097/00008390-199209000-00005. View

11.

Takahashi Y, Imahori Y, Mineura K . Prognostic and therapeutic indicator of fluoroboronophenylalanine positron emission tomography in patients with gliomas. Clin Cancer Res. 2003; 9(16 Pt 1):5888-95. View

12.

Wang H, Liao A, Deng W, Chang P, Chen J, Chen F . Evaluation of 4-borono-2-18F-fluoro-L-phenylalanine-fructose as a probe for boron neutron capture therapy in a glioma-bearing rat model. J Nucl Med. 2004; 45(2):302-8. View

13.

Chen J, Chang S, Hsu F, Wang H, Liu R . MicroPET-based pharmacokinetic analysis of the radiolabeled boron compound [18F]FBPA-F in rats with F98 glioma. Appl Radiat Isot. 2004; 61(5):887-91. DOI: 10.1016/j.apradiso.2004.05.056. View

14.

Wang H, Wu S, Chang C, Liu R, Hwang L, Lee T . Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model. Nucl Med Biol. 2005; 32(4):367-75. DOI: 10.1016/j.nucmedbio.2005.01.005. View

15.

Hsieh C, Chen Y, Chen F, Hwang J, Chen J, Liu R . Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. J Nucl Med. 2005; 46(11):1858-65. View

16.

Ishiwata K, Ido T, Honda C, Kawamura M, Ichihashi M, Mishima Y . 4-Borono-2-[18F]fluoro-D,L-phenylalanine: a possible tracer for melanoma diagnosis with PET. Int J Rad Appl Instrum B. 1992; 19(3):311-8. DOI: 10.1016/0883-2897(92)90116-g. View

17.

Havu-Auren K, Kiiski J, Lehtio K, Eskola O, Kulvik M, Vuorinen V . Uptake of 4-borono-2-[18F]fluoro-L-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET. Eur J Nucl Med Mol Imaging. 2006; 34(1):87-94. DOI: 10.1007/s00259-006-0154-y. View

18.

Popperl G, Kreth F, Mehrkens J, Herms J, Seelos K, Koch W . FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading. Eur J Nucl Med Mol Imaging. 2007; 34(12):1933-42. DOI: 10.1007/s00259-007-0534-y. View

19.

Ishiwata K, Ido T, Kawamura M, Kubota K, Ichihashi M, Mishima Y . 4-Borono-2-[18F]fluoro-D,L-phenylalanine as a target compound for boron neutron capture therapy: tumor imaging potential with positron emission tomography. Int J Rad Appl Instrum B. 1991; 18(7):745-51. DOI: 10.1016/0883-2897(91)90013-b. View

20.

Wittig A, Michel J, Moss R, Stecher-Rasmussen F, Arlinghaus H, Bendel P . Boron analysis and boron imaging in biological materials for Boron Neutron Capture Therapy (BNCT). Crit Rev Oncol Hematol. 2008; 68(1):66-90. DOI: 10.1016/j.critrevonc.2008.03.004. View